Investigating high dose buprenorphine treatment for patients using fentanyl
Safety and Efficacy of High Dose Buprenorphine Induction in Fentanyl Positive Emergency Department Patients
This study is looking at the best ways to start treatment with buprenorphine for people who are struggling with opioid use disorder and using fentanyl, to help them feel better and reduce withdrawal symptoms when they come to the emergency department.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10694220 on NIH RePORTER |
What this research studies
This research focuses on finding the best way to start treatment with buprenorphine for patients who have untreated opioid use disorder and are using fentanyl. It aims to compare different dosing strategies, including high doses, to see which is the safest and most effective in reducing withdrawal symptoms. The study will take place in emergency departments, where patients can receive immediate care. By developing specific protocols for administering buprenorphine, the research seeks to improve treatment outcomes for these patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with untreated opioid use disorder who are currently using fentanyl.
Not a fit: Patients who are not using opioids or those who have already received treatment for opioid use disorder may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients struggling with opioid use disorder, particularly those using fentanyl.
How similar studies have performed: Previous research has indicated varying success with different buprenorphine induction strategies, but this specific approach targeting fentanyl users is relatively novel.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Manini, Alex Francis — Icahn School of Medicine at Mount Sinai
- Study coordinator: Manini, Alex Francis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.